Table 3 Health care utilization by overall adherence with tobramycin inhalation solution, N = 804.
From: Adherence with tobramycin inhaled solution and health care utilization
Low utilization ≤2 cycles (n = 570) | Medium utilization >2 to <4 cycles (n = 180) | High utilization ≥4 cycles (n = 54) | |
|---|---|---|---|
Patients hospitalized (%) | 42.9% | 40.6% | 25.9% |
Median inpatient costs, IQR | $23,619 | $16,814 | $20,610 |
$11,566-55,446 | $9,527-41,021 | $8,076-64,799 | |
Median outpatient costs, (excludes drug costs) IQR | $6,317 | $5,463 | $4,033 |
$2,564-14,423 | $2,410-13,653 | $2,159-8,444 | |
Median outpatient prescription drug costs, IQR | $17,850 | $35,892 | $46,708 |
$10,353-27,260 | $27,482-46,768 | $35,125-60,969 | |
% of outpatient prescription drug costs for TIS, median | 29% | 41% | 45% |